CSI Market
Sign In | Register

Poseida Therapeutics Inc (PSTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PSTX Annual Cash Flow →
The data below summarizes Poseida Therapeutics Inc's cash flow activity from Sep 30 2023 to Sep 30 2024, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
9 Months 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Operating Activities
Income-35.41
Depreciation & amortization4.05
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue37.89
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation17.97
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Change In Fair Value Of Contingent Liabilities-
Write Off Of Deferred Debt Issuance Cost-
Increase Decrease In Operating Lease Right Of Use Assets-
Write Off Of Deferred Grant Liability-
Deferred Revenue In Operating Activities-
Loss On Contract Termination-
Accretion Of Investment Discount Net-
Increase Decrease In Operating Lease Right Of Use Asset2.67
Increase Decrease In Operating Lease Liabilities-3.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-5.74
Increase (Decrease) in Accounts Payable1.93
Increase (Decrease) in Other Accrued Liabilities-1.94
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.16
Other Working Capital0.18
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-4.70
Discontinued operations0.00
Net Cash flow from Operating Activities13.72
Investing Activities
Capital Expenditures-1.79
Sale of Capital Items0.00
Short-term Investments Proceeds-7.76
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-9.55
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.29
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.59
Net Proceeds From Grant-
Payment Of Taxes Related To Net Share Settlement Of Equity Awards-
Proceeds From Issuance Of Public Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.70
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow11.93
Total Cash Flow4.87
4 historic quarters locked

Sign in to unlock the full Poseida Therapeutics Inc cash flow history.

Sign In Create Free Account

About Poseida Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-24-123331

Figures are derived from filed reports and may be restated. Historical data is subject to revision.